Tscan: Tracking down novel T cell targets
Tscan is finding novel TCR-antigen pairs with its peptidome screening platform
Tscan is screening TCRs against a genome-wide library of antigens to systematically identify novel cancer targets for T cell therapies that avoid off-target toxicities.
"Most targets have been discovered in a one-off fashion, notably by Steve Rosenberg’s lab at the NCI," Tscan Therapeutics Inc. CEO David Southwell told BioCentury. "The barrier has been that there hasn’t been a high-throughput, whole-genome way to discover targets."
The company spun out of